LEXINGTON, Mass.--(BUSINESS WIRE)--CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, disclosed today that modification of atherosclerotic plaque with the Diamondback 360® orbital atherectomy device (Cardiovascular Systems, Inc.) improved drug uptake in calcified peripheral lesions from human cadavers. Results of this study (“Primary lesion treatment with an orbital atherectomy system enhances paclitaxel deposition in calcified peripheral arteries”) were presented yesterday by Elazer Edelman, M.D., Ph.D., Chairman and co-founder of CBSET, in a dedicated session, “Peripheral interventions”, at the “EuroPCR 2015” annual scientific meeting in Paris.
Click here for CBSET Press Kit
“We know from clinical studies that anti-restenotic drug effects are diminished in severely calcified arteries,” said Gunnar Tepe, M.D., RoMed Hospital, Rosenheim, Germany.
“The data are exciting in that they suggest that subtle modification to the plaque surface can have profound effects on drug penetration. Massive debulking may be a relic of the past, and a more muted approach may extend endovascular intervention for PAD treatment into vessels even below the knee,” said Elazer Edelman, M.D., Ph.D., Chairman and co-founder of CBSET, and a co-author of the study, added,
“A more sophisticated understanding of drug transfer after plaque modification is critically important to optimizing PAD therapies for improved clinical outcomes,” said Peter Markham, President, CEO and a co-founder of CBSET.
“This study is part of a larger effort by CBSET, MIT and collaborating companies to leverage benchtop, animal, and computational studies in order to define the barriers to drug distribution in healthy and diseased arteries,” explained Rami Tzafriri, Ph.D., principal scientist at CBSET. “While these initial findings illustrate, for the first time, the barrier effects of calcified plaque on arterial drug diffusion, they provide a path for improved therapy, as even relatively benign modification of this plaque barrier can profoundly improve drug delivery into diseased peripheral arteries.”
To learn more about this study and the services provided by CBSET, please contact: Erica Smith, Ph.D., Director, Business Development: +1-781-296-5319, esmith@cbset.org
About
Peripheral Artery Disease (PAD)
In Europe and North
America, an estimated 27 million individuals are affected with PAD,
which is caused by the accumulation of plaque in peripheral arteries
(commonly the pelvis or leg) reducing blood flow. Left untreated, PAD
can lead to severe pain, immobility, non-healing wounds and eventually
limb amputation. With risk factors such as diabetes and obesity on the
rise, the prevalence of PAD is growing at double-digit rates. Millions
of patients with PAD may benefit from treatment with orbital atherectomy
utilizing CSI’s Peripheral Orbital Atherectomy Systems, minimally
invasive catheter systems developed and manufactured by CSI. These
systems use a diamond-coated crown, attached to an orbiting shaft, which
targets atherosclerotic plaque while preserving healthy vessel tissue —
a critical factor in preventing reoccurrences. Balloon angioplasty and
stents have significant shortcomings in treating hard, calcified
lesions. Stents are prone to fractures and high recurrence rates, and
treatment of hard, calcified lesions often leads to vessel damage and
suboptimal results.
About
CBSET
CBSET — 500 Shire Way, Lexington, MA 02421 — is the
preclinical research leader in critically important therapeutic fields
such as interventional cardiology, renal disease and dialysis, chronic
drug-resistant hypertension, women’s health, minimally invasive surgery,
orthopedics, biological and synthetic tissue repair, drug delivery,
bioresorbable devices, and combination medical device and drug-eluting
products. CBSET occupies a 35,000-square-foot, state-of-the-art facility
near Boston that includes a vivarium, catheterization/imaging labs,
surgical suites, dedicated labs for SEM, histopathology/pathology, and
drug metabolism and pharmacokinetics. CBSET offers the latest equipment
for fluoroscopy, echocardiography (TEE/TTE), electrophysiology, IVUS,
optical coherence tomography (OCT), endoscopy/laparoscopy, surgical
video recording, histology, microradiography, and SEM (Scanning Electron
Microscopy).
